Literature DB >> 1052776

Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol.

L F Hill, M Davies, C M Taylor, S W Standbury.   

Abstract

Five patients with hypoparathyroidism (three post thyroidectomy and two idiopathic) were treated with synthetic 1,25-dihydroxycholecalciferol (1,25-(OH)2-D3) for up to 6 months. In each case daily oral administration of 1 microgram 1,25-(OH)2-D3, either alone or with additional calcium, raised ther serum calcium into the normal range. The serum phosphorus and the renal tubular reabsorption of phosphorus fell during treatment. None of these patients developed hypercalcaemia and no other complications of treatment have been recorded. 1,25-(OH)2D3 seems to represent a significant improvement over conventional methods for treating hypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1052776     DOI: 10.1111/j.1365-2265.1976.tb03824.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Effects of 1,25-dihydroxycholecalciferol on calcium and phosphorus metabolism in hypoparathyroidism.

Authors:  M Davies
Journal:  Calcif Tissue Res       Date:  1977-05

Review 2.  The PTH-Vitamin D-FGF23 axis.

Authors:  Jenny E Blau; Michael T Collins
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

3.  Cerebrospinal fluid absorption in primary hypoparathyroidism.

Authors:  M A Sambrook; L F Hill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-10       Impact factor: 10.154

4.  Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.

Authors:  P W Lambert; B W Hollis; N H Bell; S Epstein
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

5.  The effect of 5,6-trans-25-hydroxycholecalciferol in relative vitamin D resistancy.

Authors:  D Kraft; G Offermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

Review 6.  Update on fibroblast growth factor 23 in chronic kidney disease.

Authors:  Myles Wolf
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.